TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies (Q34734027)

4 August 2017

1 reference

title

TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies (English)

1 reference

Apostolia Maria Tsimberidou

4 August 2017

0 references

series ordinal

1

object named as

Apostolia-Maria Tsimberidou

1 reference

4 August 2017

Francis J Giles

2

1 reference

4 August 2017

1 June 2002

1 reference

Expert Review of Anticancer Therapy

4 August 2017

1 reference

4 August 2017

2

1 reference

4 August 2017

3

1 reference

4 August 2017

277-286

1 reference

A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins

4 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

Cytokine gene activity in AML cells in vivo in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2.3.277

21 January 2018

Identifiers

DOI

10.1586/14737140.2.3.277

1 reference

4 August 2017

1 reference

PubMed ID

12113051